0
Home
Products
Inquiry
Career
Who We Are
What We Are
Investors
Financial Information
Restated Financials Dec’23
Financials 2021
Financials 2022
Financials 2023
Interim Financials Dec’23
Financials 2024
Interim Financials Sep’24
Restated Financials Sep’24
Audited Financials March 31,2025
Unaudited Financial Statement Ending September 30, 2025
General Meeting Highlights
Notice of Annual General Meeting
AGM FY 25
Proceedings of General Meeting
Voting Results and Scrutinizer's Report
General Meeting Highlights
Notice of Annual General Meeting
Proceedings of General Meeting
Voting Results and Scrutinizer's Report
Annual Report
Annual Reports
FY 2018-19
FY 2019-20
FY 2020-21
FY 2021-22
FY 2022-23
FY 2023-24
FY 2024-25
MGT-7
FY 2018-19
FY 2019-20
FY 2020-21
FY 2021-22
FY 2022-23
FY 2023-24
FY 2024-25
Investor Information
Corporate Governance
Corporate Governance
Board of Directors
Terms and Condition for Appointment of Independent Director
KMP
SMP
Committee of Board of Directors
Policies
Archival Policy
Board Diversity Policy
Code of Conduct - Policy
Code of Fair Disclosure of Unpublished Price Sensitive Information
Corporate Governance
Familiarisation_Programme
Insider Trading Policy
Materiality Policies for group company, Creditors, Litigation
Nomination and Remuneration Policy
Policy and Procedures for Inquiry in Case of Leak or Suspected Leak of UPSI
Policy on Dealing with Related Party Transactions
Policy on Preservation of Documents
Policy on Materiality events
Risk Assessment and Management Policy
Terms and Conditions of Appointment of Independent Directors
Vigil Mechanism & Whistle Blower Policy
Sexual Harassment
CSR Policy
Others
Material Contract
Tripartite Agreement
NSDL
CDSL
RTA Agreement
Offer Agreement
Market Maker Agreement
Underwriter Agreement
Syndicate Agreement
Share Escrow Agreement
Public Offer Agreement
Material Documents
Examination report of Independent Auditor on Restated Financials
Material Creditors
Management Team Information
Consents
Promoters
Directors
Selling shareholders
Book Running Lead Manager
Registrar to the Offer
Bankers of the Company
Company Secretary & Compliance Officer
Chief Financial Officer
Legal Counsel
COI
25-Jan-2024
21-Aug-2017
Authorization letter from selling shareholders
Carrying & Forwarding Agency Agreement
Due Diligence Certificate
Details of Directorships and full-time positions in Body Corporates held by Directors
Stock Exchange Compliances
Disclosure of Material Events or Information
AMWILL Reg. 30 Disclosure March 31, 2025
AMWILL Reg. 30 Disclosure April 10, 2025
AMWILL Reg. 30 Disclosure April 16, 2025
AMWILL Reg. 30 Disclosure May 10, 2025
AMWILL Reg. 29 Intimation May 26, 2025
AMWILL Reg. 30 & 33 Disclosure May 29, 2025
AMWILL - Media Release - 30/06/2025
AMWILL Reg. 30 Disclosure July 08, 2025
AMWILL Reg. 29 Intimation October 24, 2025
AMWILL Reg. 29 Intimation October 30, 2025
AMWILL Reg. 30 Disclosure November 04, 2025
AMWILL Reg. 30 Disclosure January 16, 2026
AMWILL Reg. 30 Disclosure February 09, 2026
AMWILL Reg. 30 Disclosure February 18, 2026
AMWILL Reg. 30 Disclosure April 07, 2026
Trading Window Intimation
September 30,2025
March 31, 2026
Shareholding Pattern
Q4 FY25
H1 FY 26
H2 FY26
Related Party Transaction
Half yearly March 31,2025
Half yearly ended september 30,2025
Statement of Deviation or Variation in Utilization of funds raised through Initial Public Offer ("IPO")
Quarter ended March 31, 2025
Half yearly ended September 30, 2025
Reconciliation of Share Capital Audit Reports
Quarter ended March 31, 2025
Quarter ended June 30, 2025
Quarter ended September 30, 2025
Quarter ended December 31, 2025
Quarter ended March 31, 2026
Integrated Filing (Governance)
Quarter ended March 31, 2025
Quarter ended June 30, 2025
Quarter ended September 30, 2025
Quarter ended December 31, 2025
Quarter ended March 31, 2026
Familiarization Programme for Independent Directors
Familiarisation Programme for Independent Directors
Smart ODR
SEBI Circular on ODR
Click here to access SMART ODR portal
IPO
DRHP
RHP
Prospectus
Resolutions
Special resolution for Increase of Authorised Capital
Board resolution for approval and adoption of DRHP
Board resolution for approval and adoption of KPIs
Board resolution for approval of consent from selling shareholders
Special Resolution for Appointment of Managing Director
Board resolution for Appointment of Managing Director
Newspaper Advertisement
Newspaper Advertisement: Pre-Dispatch of Notice for 8th Annual General Meeting (AGM) 2025
Newspaper Advertisement: Post-Dispatch of Notice for 8th Annual General Meeting (AGM) 2025
Charter Documents
Memorandum of Association
Article of Association
Contact Us
Login
Register
Anti Histaminics
All Category
Anti Histaminics
AVERTICH M TABLETS
117.00
View Details
EAZEURT -25 TABLETS 25 MG
67.00
Add To Cart
View Details
EAZEURT -10 TABLETS 10 MG
33.00
Add To Cart
View Details
URTIBIL 40 TABLETS
178.00
Add To Cart
View Details
HISTOCROSS 180 TABS
159.00
Add To Cart
View Details
HISTOCROSS L TABS 10 MG
65.00
Add To Cart
View Details
HISTACROSS-L TABS 5 MG
56.00
Add To Cart
View Details
AMVIBAST-20 TABLETS 20 MG
84.00
Add To Cart
View Details
AVERTICH TABLETS 10 MG
70.00
Add To Cart
View Details
1
2
Next
Back To Product Category
